株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

転移性前立腺がん:パイプライン分析

Metastatic Prostate Cancer - Pipeline Review, H2 2015

発行 Global Markets Direct 商品コード 251588
出版日 ページ情報 英文 95 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.58円で換算しております。
Back to Top
転移性前立腺がん:パイプライン分析 Metastatic Prostate Cancer - Pipeline Review, H2 2015
出版日: 2015年07月31日 ページ情報: 英文 95 Pages
概要

転移性前立腺がんとは、前立腺から人体の他の部位に転移した進行がんです。主な症状として、骨痛や腰痛・骨盤痛、体重減少、嗜眠、リンパ節の肥大化、皮膚・腸からの出血などが挙げられます。主な治療法には、外科手術やホルモン療法、化学療法、放射線療法などがあります。

当レポートでは、世界各国での転移性前立腺がん治療用のパイプライン製品の開発状況について分析し、製品開発・上市の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要、最新の業界動向などの情報をお届けします。

目次

イントロダクション

  • 分析範囲

転移性前立腺がんの概要

治療薬の開発

  • 転移性前立腺がん向けパイプライン製品:概要
  • 転移性前立腺がん向けパイプライン製品:比較分析

各企業で開発中の転移性前立腺がん治療薬

大学/研究機関で研究中の転移性前立腺がん治療薬

パイプライン製品の概略

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

転移性前立腺がん治療薬:開発中の製品の一覧(企業別)

転移性前立腺がん治療薬:研究中の製品の一覧(大学/研究機関別)

転移性前立腺がん治療薬の開発に従事している企業

  • Actinium Pharmaceuticals, Inc.
  • Camurus AB
  • Dongkook Pharmaceutical Co., Ltd.
  • Eli Lilly and Company
  • EntreChem, S.L.
  • Johnson & Johnson
  • MedImmune, LLC
  • MEI Pharma, Inc.
  • Merck & Co., Inc.
  • OncoMax
  • OXiGENE, Inc.
  • Progenics Pharmaceuticals, Inc.
  • ValiRx Plc

転移性前立腺がん:治療薬の評価

  • 単剤治療薬の場合
  • 標的別
  • 作用機序別
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • abiraterone acetate
  • Actimab-P
  • AST-VAC-1
  • CADD-522
  • Cell Therapy to Target PSMA for Metastatic Prostate Cancer
  • EC-7073
  • HepIn-13
  • KGP-94
  • landogrozumab
  • leuprolide acetate
  • MEDI-6469
  • MIP-1095
  • MVI-118
  • OMRCA-01
  • pracinostat
  • Recombinant Protein for Oncology
  • triptorelin pamoate
  • Vaccine For Oncolytic Newcastle Disease Virus
  • VAL-201
  • vorinostat

転移性前立腺がん治療薬:パイプライン製品の最新動向

転移性前立腺がん治療薬:開発が休止状態の製品

転移性前立腺がん治療薬:開発が中止された製品

転移性前立腺がん関連製品の開発のマイルストーン

  • 注目すべき最新動向・プレスリリース

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC6865IDB

Summary

Global Markets Direct's, 'Metastatic Prostate Cancer - Pipeline Review, H2 2015', provides an overview of the Metastatic Prostate Cancer's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Metastatic Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Metastatic Prostate Cancer and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Metastatic Prostate Cancer
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Metastatic Prostate Cancer and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Metastatic Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Metastatic Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Metastatic Prostate Cancer
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Metastatic Prostate Cancer pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Metastatic Prostate Cancer Overview
  • Therapeutics Development
    • Pipeline Products for Metastatic Prostate Cancer - Overview
    • Pipeline Products for Metastatic Prostate Cancer - Comparative Analysis
  • Metastatic Prostate Cancer - Therapeutics under Development by Companies
  • Metastatic Prostate Cancer - Therapeutics under Investigation by Universities/Institutes
  • Metastatic Prostate Cancer - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Metastatic Prostate Cancer - Products under Development by Companies
  • Metastatic Prostate Cancer - Products under Investigation by Universities/Institutes
  • Metastatic Prostate Cancer - Companies Involved in Therapeutics Development
    • Actinium Pharmaceuticals, Inc.
    • Camurus AB
    • Dongkook Pharmaceutical Co., Ltd.
    • Eli Lilly and Company
    • EntreChem, S.L.
    • Johnson & Johnson
    • MedImmune, LLC
    • MEI Pharma, Inc.
    • Merck & Co., Inc.
    • OncoMax
    • OXiGENE, Inc.
    • Progenics Pharmaceuticals, Inc.
    • ValiRx Plc
  • Metastatic Prostate Cancer - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • abiraterone acetate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Actimab-P - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • AST-VAC-1 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CADD-522 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cell Therapy to Target PSMA for Metastatic Prostate Cancer - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • EC-7073 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • HepIn-13 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • KGP-94 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • landogrozumab - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • leuprolide acetate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MEDI-6469 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MIP-1095 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • MVI-118 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • OMRCA-01 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pracinostat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Protein for Oncology - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • triptorelin pamoate - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Vaccine For Oncolytic Newcastle Disease Virus - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VAL-201 - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • vorinostat - Drug Profile
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Metastatic Prostate Cancer - Recent Pipeline Updates
  • Metastatic Prostate Cancer - Dormant Projects
  • Metastatic Prostate Cancer - Discontinued Products
  • Metastatic Prostate Cancer - Product Development Milestones
    • Featured News & Press Releases
      • Jun 01, 2015: Cleveland Clinic Researcher Discovers Metabolite of Prostate Cancer Drug more Effective at Treating Aggressive Tumors
      • Mar 27, 2014: OXiGENE Announces Presentation of Preclinical Abstracts at 2014 AACR Conference
      • Feb 06, 2014: ZYTIGA Now Reimbursed in Quebec for Use Prior to Chemotherapy in Men with Metastatic Prostate Cancer
      • Nov 21, 2013: ZYTIGA Now Available for Men with Metastatic Prostate Cancer in British Columbia Prior to Chemotherapy
      • May 29, 2013: Janssen's Zytiga Receives New Indication Approval From Health Canada For Treatment Of Metastatic Prostate Cancer
      • Jun 02, 2012: Zytiga's Phase III Results Show Significant Improvement In Radiographic Progression-Free Survival And Trend For Increased Overall Survival In Metastatic Prostate Cancer Patients
      • May 16, 2012: J&J's ZYTIGA Now Available For Eligible Patients In Nova Scotia, Newfoundland And Labrador For Prostate Cancer
      • Mar 04, 2005: Geron Announces Publication Of Phase 1-2 Telomerase Vaccine Study Results In Patients With Metastatic Prostate Cancer
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Metastatic Prostate Cancer, H2 2015
  • Number of Products under Development for Metastatic Prostate Cancer - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Late Stage Development, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Development, H2 2015
  • Products under Development by Companies, H2 2015
  • Products under Investigation by Universities/Institutes, H2 2015
  • Metastatic Prostate Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H2 2015
  • Metastatic Prostate Cancer - Pipeline by Camurus AB, H2 2015
  • Metastatic Prostate Cancer - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2015
  • Metastatic Prostate Cancer - Pipeline by Eli Lilly and Company, H2 2015
  • Metastatic Prostate Cancer - Pipeline by EntreChem, S.L., H2 2015
  • Metastatic Prostate Cancer - Pipeline by Johnson & Johnson, H2 2015
  • Metastatic Prostate Cancer - Pipeline by MedImmune, LLC, H2 2015
  • Metastatic Prostate Cancer - Pipeline by MEI Pharma, Inc., H2 2015
  • Metastatic Prostate Cancer - Pipeline by Merck & Co., Inc., H2 2015
  • Metastatic Prostate Cancer - Pipeline by OncoMax, H2 2015
  • Metastatic Prostate Cancer - Pipeline by OXiGENE, Inc., H2 2015
  • Metastatic Prostate Cancer - Pipeline by Progenics Pharmaceuticals, Inc., H2 2015
  • Metastatic Prostate Cancer - Pipeline by ValiRx Plc, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Stage and Target, H2 2015
  • Number of Products by Stage and Mechanism of Action, H2 2015
  • Number of Products by Stage and Route of Administration, H2 2015
  • Number of Products by Stage and Molecule Type, H2 2015
  • Metastatic Prostate Cancer Therapeutics - Recent Pipeline Updates, H2 2015
  • Metastatic Prostate Cancer - Dormant Projects, H2 2015
  • Metastatic Prostate Cancer - Dormant Projects (Contd..1), H2 2015
  • Metastatic Prostate Cancer - Discontinued Products, H2 2015

List of Figures

  • Number of Products under Development for Metastatic Prostate Cancer, H2 2015
  • Number of Products under Development for Metastatic Prostate Cancer - Comparative Analysis, H2 2015
  • Number of Products under Development by Companies, H2 2015
  • Number of Products under Investigation by Universities/Institutes, H2 2015
  • Comparative Analysis by Clinical Stage Development, H2 2015
  • Comparative Analysis by Early Stage Products, H2 2015
  • Assessment by Monotherapy Products, H2 2015
  • Number of Products by Top 10 Targets, H2 2015
  • Number of Products by Stage and Top 10 Targets, H2 2015
  • Number of Products by Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
  • Number of Products by Top 10 Routes of Administration, H2 2015
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2015
  • Number of Products by Top 10 Molecule Types, H2 2015
  • Number of Products by Stage and Top 10 Molecule Types, H2 2015
Back to Top